| Title |
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
|
|---|---|
| Published in |
Drug Safety, December 2017
|
| DOI | 10.1007/s40264-017-0622-2 |
| Pubmed ID | |
| Authors |
Abril Verden, Mo Dimbil, Robert Kyle, Brian Overstreet, Keith B. Hoffman |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 2 | 18% |
| United Kingdom | 2 | 18% |
| United States | 2 | 18% |
| New Zealand | 1 | 9% |
| Turkey | 1 | 9% |
| France | 1 | 9% |
| Unknown | 2 | 18% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 4 | 36% |
| Members of the public | 4 | 36% |
| Scientists | 2 | 18% |
| Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 112 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 14% |
| Student > Ph. D. Student | 14 | 13% |
| Student > Master | 11 | 10% |
| Other | 10 | 9% |
| Student > Postgraduate | 9 | 8% |
| Other | 30 | 27% |
| Unknown | 22 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 15% |
| Unspecified | 9 | 8% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Nursing and Health Professions | 3 | 3% |
| Other | 10 | 9% |
| Unknown | 30 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2023.
All research outputs
#1,916,995
of 26,017,215 outputs
Outputs from Drug Safety
#187
of 1,888 outputs
Outputs of similar age
#41,683
of 451,499 outputs
Outputs of similar age from Drug Safety
#3
of 21 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,888 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,499 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.